FDA approves Novartis' gene therapy for rare muscle disorder
ReutersNov 24, 2025 10:22 PM
Nov 24 (Reuters) - U.S. Food and Drug Administration has approved Novartis' NOVN.S gene therapy for a type of rare muscle disorder, the drugmaker said on Monday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
U.S. September PCE: Likely to Fall Short of Expectations, Bullish for US Stocks
TradingKey - Currently, the market widely anticipates that the core PCE year-on-year growth rate for September will stand at 2.9%, and we expect the upcoming data to be slightly below this consensus forecast.TradingKey
Tue, Nov 25
Palantir: Why PLTR Is So Notorious, Its Stock Performance, and If It's a Buy
TradingKey — Palantir Technologies Inc. (PLTR) stock maintains its investment appeal, with analysts recommending buying on dips as valuation corrections and consistently strong earnings bolster its long-term prospects. While short-term volatility is driven by a cooling AI narrative and adjustments tTradingKey
Fri, Nov 21
The U.S. Dollar Index Is the Key Driver of Gold Prices: Where Are the Dollar and Gold Headed Next?
TradingKey - The strength or weakness of the U.S. Dollar Index stands as the core determinant shaping gold's trajectory.TradingKey
Fri, Nov 21
Alibaba FY2026Q2 Earnings Preview: The Great Pivot from E-Commerce Giant to AI Powerhouse
TradingKey - As Alibaba's earnings approach, one question dominates: Can AI and quick commerce justify sacrificing profits now for future dominance? Preview how the RMB 50 billion quick commerce push, 35.8% AI cloud share, and fierce competition could decide if BABA's 88% rally holds.TradingKey
Thu, Nov 20
U.S. September Nonfarm Payrolls: Two-Scenario Analysis, Will U.S. Stocks Diverge in Short-Term and Medium-to-Long-Term Trends?
TradingKey - This paper conducts an analysis of the U.S. September nonfarm payroll data and the subsequent employment market through two scenario-based assessments, alongside a short-term and medium-to-long-term outlook for U.S. stocks.TradingKey
Tue, Nov 18
